Objective To investigate the scavenging abilities of ginkgo albumin to reactive oxygen in vitro, as well as the protection and mechanism of ginkgo albumin on damaged DNA. Methods Lotus Seedpod Procyanidin (LSPC) and bovine serum albumin (BSA) were used as control sample, the effect of ginkgo albumin on removal of superoxide anion was determined by Pyrogallol-Luminol system. Scavenging ability of ginkgo albumin on hydroxide free radical was determined by CuSO4-Phen-Vc-H2O2, FeSO4-Luminol-H2O2, and FeSO4-Luminol systems. Luminol-H2O2 system was used to measure the scavenging effect on hydrogen peroxide. Preventive effect of ginkgo albumin on in vitro damaged DNA was determined by CuSO4-Phen-Vc-H2O2-DNA system. Results Ginkgo albumin possessed a good scavenging potency on reactive oxygen and protection on damaged DNA, but promoted oxidation in the FeSO4-Luminol-H2O2 and Luminol-H2O2 chemiluminescence systems. Conclusion Not every chemiluminescences system is suitable for investigating the antioxidant activity of ginkgo albumin.

Objective To evaluate the clinical effects of block calculus extraction catheter in the ureteroscopic lasertripsy. Methods Two hundred and thirty patients with ureter calculus were enrolled. Ninety-six patients were treated with block calculus extraction catheter (test group), and 134 patients were treated without block calculus extraction catheter (control group). The patients in 2 groups were treated with holmium laser ureteroscopic lithotripsy of Lumenis PowerSuite60W, and the treatment effectiveness was compared. Results The operation time and primary stone clearance rate in test group were significantly better than those in control group: (23.3 ± 7.4) min vs. (35.6 ± 11.1) min, 98.92%(92/93) vs. 88.89%(112/126), and there were significantly differences (P<0.01). The bleeding amounts and fever rate of 2 groups had no significant difference (P > 0.05). Conclusions The block calculus extraction catheter is very useful and safe in preventing the calculus shift, shortening the operation time and improving the calculus elimination rate .

ObjectiveTo review the major complications in patients after transurethal electrovaporization of the prostate (TUVP) and transurethal plasmakinetic resection of the prostate (PKRP) retrospectively and to analyze the causes and management.MethodsClinical data of 92 cases of patients after TUVP and 226 cases after PKRP were reviewed retrospectively.The patients' relevant circumstances including subjective symptoms,objective indexes and the major long-term complications were followed up about 1-,3-,and 5-year after operation.Different therapeutic methods were chosen according to different causes of the complications.ResultsThere were no significant differences (P ＞ 0.05 ) between TUVP group and PKRP group in IPSS (7.3±2.8,7.2±2.5),QOL (2.6±0.7,2.7 ±0.5),Qmax[ (25.2±3.5),(25.5 ±3.8) ml/s] and PVR [(18.7 ±5.4),(17.8 ±6.3)ml].The incidences of bladder neck restriction was about 1.1％,3.3％,and 2.3％ after 1,3,and5 years in patients after TUVP,and 0.9％,2.7％,and 1.8％ after PKRP accordingly.For urethral stricture,it was about 3.3％,2.2％,and 1.1％ after TUVP,and 3.1％,2.2％,and 0.9％ after PKRP.For residual prostatic hyperplasia,it was about 1.1％,2.2％,and 4.5％ after TUVP,and 1.3％,2.7％,and 3.7％ after PKRP accordingly.ConclusionsTUVP and PKRP are effective and safe treatment options for BPH.The major long-term complications after TUVP and PKRP are bladder neck restriction,urethral stricture and residual prostatic hyperplasia.Regular and long-term follow-up is required for patients after TUVP and PKRP.Different therapeutic methods should be chosen according to different causes of the complications after operation.

Objective To evaluate the efficacy and safety of solifenacin in the treatment of overactive bladder (OAB) syndrome in patients who have undergone transurethral resection of the prostate (TURP). Methods According to the Overactive Bladder Symptom Score (OABSS), 64 cases with OAB symptoms after TURP were randomly assigned into study and control groups with 32 cases in each group. Patients in the study group were treated with solifenacin (5 mg once daily) for a two week period beginning the first day after catheter removal. Patients in the control group were not treated with solifenacin. The mean urgency episodes, micturition episodes, nocturia, urge incontinence, volume voided per micturition, Qmax and OABSS scores were recorded on the 7th and the 14th day after catheter removal. Treatment-emergent adverse events with solifenacin in the study group were recorded and evaluated as well. All cases were followed-up for 8 weeks after catheter removal. Results There were statistically significant differences (P<0.01) in favor of the study group over the control group in the aspect of urgency, micturition episodes, nocturia, urge incontinence, volume voided per micturition and OABSS scores. The incidences of treatment related adverse events were 12.5% (4/32) in the study group with no serious adverse event observed. Conclusions Solifenacin is effective in the treatment of OAB syndrome after TURP and is well tolerated as well. Application of solifenacin should be recommended earlier after TURP.